Skip to main content

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Recruiting · Phase 3 · NCT06585410

Conditions: Cutaneous Squamous Cell Carcinoma (CSCC)

At a glance

Research payments reported, 2025
$1.6M
U.S. investigators named
33
Sites paid
32
Planned or actual enrollment
369

About the trial

Sponsor
Regeneron Pharmaceuticals
Tested
Cemiplimab (drug), Standard of care (procedure)
Dates
Started 2025-01-02; completion 2030-05-03
Results posted
Not yet

This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works compared to surgery

From ClinicalTrials.gov, last updated 2026-09-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $1.6M in research payments for this study in 2025 (1,006 payments).

Products named: Libtayo

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Ut MD Anderson Cancer Center $222,275
  • Integrity Research Clinical Associates LLC $168,136
  • $157,267
  • Dana Farber Mass General Brigham Cancer Care Inc $89,852
  • Rochester Dermatologic Surgery $86,195
  • University of California San Diego $65,228
  • Mayo Clinic Hospital, AZ $64,226
  • Cutaneous Clinical Trials LLC $52,308
  • Hospital of Univ of Pennsylvania, PA $47,553
  • Mymichigan Medical Center Midland, MI $45,086
  • Southwest Skin Specialists LLC $45,039
  • The George Washington University $43,319
  • Reveal Research Institute $40,484
  • Board of the Leland Stanford $38,284
  • Stryde Consulting LLC $38,125
  • The University of Chicago $34,142
  • Washington University $34,079
  • University of New Mexico $29,005
  • Trustees of Columbia University in The City of New York $27,541
  • Corazon USA LLC $26,726
  • Pennsylvania State University $24,975
  • Ascension Seton Medical Center Austin, TX $23,842
  • Dermatology Health Specialists PC $21,455
  • Clinical Research Center of the Carolinas $21,330
  • Dermatology and Skin Cancer Specialists LLC $20,597
  • Equity Medical LLC $17,796
  • Ohsu Hospital and Clinics, OR $16,011
  • Dermassociates PC $15,678
  • Oak Dermatology LLC $14,405
  • Las Vegas Dermatology $14,048
  • Dawes Fretzin Clinical Research Group LLC $11,540
  • Derm Center $6,011
  • University of South Florida $5,164

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.